CORRESPONDENCE
Ischemia-reperfusion (I/R) damage develops when liver blood fl ow is interrupted, or severely diminished, for a long period of time and then restarted. Ischemia may induce cell death by itself by causing ATP depletion, but mainly primes the cells for the more intense damage that occurs when the liver is reperfused (1) . Upon reentry of oxygen, uncoupled dysfunctional mitochondria produce large amounts of oxygen-free radicals, intense oxidative stress, and mitochondrial permeability transition leading to cell death (1) . On reperfusion activation of Kupff er cells also occurs, leading to abundant production of reactive oxygen species and proinfl ammatory cytokines, further enhancing organ damage (1) . I/R injury can cause cell death by apoptosis or necrosis (1) depending on the intensity of ATP depletion. I/R liver damage is of great clinical importance because it can cause primary graft nonfunction after liver transplantation and may critically compromise the function of the remaining liver after major hepatic resections (2) . The development of new therapeutic approaches to control I/R injury may benefi t from better understanding of the defensive mechanisms set into motion in the liver when it is subjected to ischemic insults.
In the liver, and in various tissues, it has been shown that a short period of ischemia protects effi ciently against subsequent I/R injury (3) . This phenomenon, known as ischemic preconditioning (IP), indicates that a brief ischemic insult triggers a protective biological reaction in the liver which is associated with inhibition of proapoptotic pathways (3, 4) . Although several mechanisms have been invoked, there is increasing evidence supporting that a sublethal oxidative stress, as occurs during a short
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ischemic interval, plays a crucial role in the induction of IP (4) . In this regard recent reports have demonstrated that the protective eff ect granted by IP on subsequent ischemic injury can be mimicked by treatment with H 2 O 2 or an H 2 O 2 analogue (5, 6). However, the downstream eff ectors of the protective action of reactive oxygen species are still not known.
Cardiotrophin (CT)-1 is member of the IL-6 family of cytokines that binds to a specifi c receptor that contains gp130 and leukemia inhibitory factor receptor (7). gp130 is common to the receptor complex of other members of IL-6 superfamily and is required for both ligand binding and signal transduction (7) . CT-1 is expressed by both parenchymal and nonparenchymal liver cells and exerts potent antiapoptotic eff ects on hepatocytes (8) . In these cells, as in cardiomyocytes and neurons, CT-1 activates cell survival signaling pathways including STAT3, extracellular-regulated kinase (Erk)1/2, and protein kinase B (Akt) (8) (9) (10) . In the present work we have analyzed the possible role of CT-1 as a natural defense of the liver against I/R injury.
RESULTS AND DISCUSSION Treatment with recombinant CT-1 reduces I/R liver injury
To determine if CT-1 was able to attenuate I/R injury, 400 μg/kg of body weight of recombinant rat CT-1 (rCT-1) was administered to Wistar rats 10 min before clamping the artery of the medium and left liver lobes. Samples were obtained at 6 h of reperfusion after 1 h of ischemia. We found that although untreated rats showed a marked rise of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and exhibited large areas of necrosis in the liver biopsy, those that were pretreated with CT-1 showed little variation of transaminases and no relevant histological changes in the liver parenchyma (Fig. 1, A and B) . Subsequent determination of transaminases levels at 12 h of reperfusion showed maintained low values in rats pretreated with rCT-1 but high levels in untreated animals (unpublished data).
In another set of experiments rCT-1 at the dose of 800 μg/kg of body weight was given at the time of reperfusion after 1 h of ischemia. In these cases serum transaminases at 12 h of reperfusion were higher than in animals that received CT-1 before ischemia, but still there was significant (P < 0.05) protection compared with untreated rats (ALT: 5,726 ± 2,765 and 1,904 ± 478 in untreated and rCT-1-treated animals, respectively). These fi ndings and our previous data showing that CT-1 was able to abrogate concanavalin A-induced hepatitis (8) indicate that this cytokine is able to exert hepatoprotective activity against diverse forms of liver damage. 
BRIEF DEFINITIVE REPORT
CT-1 is an essential endogenous defense of the liver against I/R injury Next, we wished to determine if CT-1 might be involved in the natural biological process that defends the liver against ischemia. To this aim we subjected CT-1-defi cient mice to 75-min ischemia of the left and median lobes followed by reperfusion. We observed that the rise of serum transminases and the severity of hemorrhagic necrosis in the liver tissue that was exposed to ischemia were more intense in CT-1-null mice than in WT animals when analyzed at 3 h of reperfusion ( Fig. 1, C and D) . The higher sensitivity to I/R damage exhibited by CT-1-defi cient mice was not caused by some abnormality diff erent from the lack of this cytokine, because these mice were protected against I/R injury by administration of rCT-1 in the same manner as normal animals ( Fig. 1 , C and D). In rCT-1-treated mice (both WT and CT-1-null animals) serum ALT levels at 6 and 24 h after reperfusion remained signifi cantly (P < 0.05) lower than in untreated animals (unpublished data), indicating that CT-1 treatment eff ectively prevented tissue injury and did not merely delay it. These data reveal an up to now unrecognized role of CT-1 as a natural defense of the liver against I/R damage.
CT-1 is a key executor of liver protection induced by ischemic preconditioning
The role played by CT-1 in liver defense against I/R prompted us to investigate if this cytokine could be a mediator of the protective biological response induced by IP. We observed that when the left and median liver lobes of normal mice were subjected to a brief period of ischemia and 15 min of reperfusion (IP) followed by 75 min of ischemia and 3 h of reperfusion (I/R injury), the histological liver lesion, the number of apoptotic hepatocyte nuclei (as estimated by the terminal deoxynucleotide transferase-mediated dUDP nick-end labeling [TUNEL] technique), and the rise of serum transaminases were markedly reduced compared with those shown by animals exposed to I/R insult without previous IP (Fig. 2, A-C) . It has been reported that I/R damage is associated with phosphorylation of c-Jun-NH 2 -terminal kinase (JNK), an oxidative stress-responsive kinase activated during IR liver injury (11, 12) , and with activation of the proapoptotic caspase 3, a critical executor of I/R liver damage (13, 14) . We found that although I/R injury caused activation of caspase 3 and phosphorylation of JNK and c-Jun in liver tissue, these events did not occur when I/R was preceded by IP (Fig. 2 D) .
In contrast to WT mice, IP lacked protective eff ect in CT-1-defi cient mice. In these animals the rise of serum transaminases, the intensity of the histological liver damage, the abundance of TUNEL-positive hepatocyte nuclei, and the activation of caspase 3, JNK, and c-Jun in hepatic tissue after I/R were similar in all mice independently of whether they had previous exposure to IP or not (Fig. 2, A-D) .
STAT3 promotes antiapoptotic eff ects in many tissues including the liver (15) , and it has been shown that the gp130-STAT3 signaling pathway mediates the hepatoprotection induced by gp130 ligands (16) . There is also evidence implicating STAT3 activation in the development of heart and brain protection associated with ischemic preconditioning (17, 18) , but the mechanisms by which STAT3 is activated in response to IP remain ill understood. In the present work we found activation of STAT3 in hepatic tissue in association with liver protection against I/R injury. Thus, marked STAT3 phosphorylation together with nuclear translocation of STAT3 in hepatocytes were found in normal mice exposed to I/R challenge preceded by IP or rCT-1 administration but not in those subjected to I/R without previous treatment (Fig. 3, A and B) . In contrast, IP was unable to induce STAT3 activation in CT-1-null mice in accordance with the absence of protective eff ect of IP in these animals. However, there was prominent phosphorylation and nuclear translocation of STAT3 in livers from CT-1-null mice after I/R when the animals were pretreated with rCT-1 (Fig. 3, A and B) , a therapy that aff orded protection against I/R injury.
Although it has been reported that rCT-1 may defend cardiac cells against hypoxic damage (19) and neurones against oxidative injury (20) , there was no information as to whether endogenous CT-1 participates in the biological protective response elicited by IP. Our results in CT-1-defi cient mice reveal that CT-1 is a critical mediator of STAT3 activation and nuclear translocation in animals exposed to IP and that CT-1 is an essential component of the hepatoprotective reaction set into motion by IP.
Administration of neutralizing antibodies to CT-1 blunt the protective effect of IP
Once we found that CT-1 was a critical component of the defensive mechanism promoted by IP, we wished to determine whether the IP could aff ect the expression of CT-1 in liver tissue. We observed that the hepatic levels of CT-1 protein did not change after 10 min of ischemia and 15 min of reperfusion (Fig. 4 A) , suggesting that IP has no manifest effect on CT-1 synthesis. We reasoned that IP might provoke the release of preformed cytokine to the extracellular milieu to induce local autocrine and paracrine eff ects. To evaluate this possibility we performed an experiment consisting of the administration of neutralizing anti-CT-1 antibodies to mice subjected to IP followed by I/R. In agreement with our previous observation showing that IP was not eff ective in CT-1 −/− mice (Fig. 2, A-D) , neutralization of CT-1 in WT mice signifi cantly (P < 0.05) blunted the protective eff ect of IP on I/R liver injury. This was indicated by the rise in serum AST and ALT levels, and by the activation of caspase 3 in the liver of mice treated with anti-CT-1 antibody compared with controls (IgG) (Fig. 4, B and C) . Anti-CT-1 antibody administration to sham-operated mice had no eff ect on serum transaminases levels (unpublished data). These observations further confi rmed the hepatoprotective role of CT-1, and also suggested that CT-1 must be released from intracellular stores to the extracellular milieu to mediate the hepatoprotective eff ects of IP. We were unable to detect by ELISA circulating CT-1 either in basal condition or after IP (unpublished data). It seems possible that CT-1 may act mainly paracrinally during IP.
Oxidative stress induces the release of CT-1 from hepatocytes to extracellular milieu It has been shown that a sublethal oxidative stress is a key event that mediates the cytoprotective eff ect of IP in the liver (5, 6) . Sublethal concentrations of oxygen-free radicals, likely produced by Kupff er cells (6) , are thought to trigger protective mechanisms on subsequent periods of ischemia; however, the identity of such mechanisms remains elusive (5) . Therefore, we analyzed whether isolated hepatocytes from normal mice could release CT-1 upon exposure to a prooxidant such as the H 2 O 2 analogue tert-butyl-hydroperoxide (tBuOOH), previously shown to mimic the eff ect of IP in mice (5) . Western blot analysis of the supernatant of cultured hepatocytes at 30 and 60 min of incubation showed absence of CT-1 in the medium of nonstimulated cells, whereas a strong signal was observed at 60 min of incubation with tBuOOH (Fig. 4 D) . A slight increase in the intracellular levels of CT-1 protein was observed after 60 min of treatment with tBuOOH (Fig. 4 D) . This could be interpreted as a compensatory response to replenish intracellular stores of CT-1 after oxidative stress-stimulated release of this cytokine. From these observations it is conceivable that the oxidative stress generated during IP is responsible for the release of CT-1 to extracellular milieu. Our present data shed light on the mechanism by which oxidative stress promotes IP-induced hepatoprotection by showing that this event leads to CT-1 release, and that this cytokine is essential for the cytoprotective eff ect to occur because it is absent in CT-1-null mice. 
BRIEF DEFINITIVE REPORT

CT-1 but not IL-6 mediates the liver defense against brief ischemia
The phenomenon of IP indicates that normal livers tolerate a short period of ischemia (and reperfusion) well by setting into motion protective mechanisms that adapt the phenotype of the tissue not only to resist this brief I/R insult but also to acquire tolerance to subsequent I/R of longer duration. The inability of CT-1-null mice to elicit protective IP suggests that CT-1 might also be essential to defend the liver against ischemia of short duration. Because IL-6 has been suggested to play a role in the modulation of I/R liver damage, and treatment with recombinant IL-6 substantially protects from ischemic liver injury (21), we decided to compare the relative role of CT-1 and IL-6 in the defense of the liver against brief I/R. To this aim we exposed the left and median lobes of the liver of WT mice, CT-1-null mice, and IL-6-null mice to 10 min of ischemia followed by 15 min of reperfusion, and at the end of this time we analyzed serum AST and ALT values and the activation of survival factors STAT3 and Akt in hepatic tissue. We observed that in both WT and IL-6-null mice AST and ALT levels showed little change with respect to control values. This resistance to short I/R exposure was associated with STAT3 and Akt activation in the two groups of animals, although with less intensity in IL-6-defi cient mice (Fig. 5, A and B) . In sharp contrast, in CT-1-null mice AST and ALT were considerably elevated and there was no sign of STAT3 activation and only a faint signal of phosphorylated Akt (Fig. 5, A and B) . This fi nding reveals that CT-1, rather than IL-6, is a critical factor in the defense of the liver against ischemia of short duration.
The role of CT-1 as a natural defense against I/R liver injury and the ability of rCT-1 to protect against this form of hepatocellular damage point to potential therapeutic applications of rCT-1. New eff ective therapies are urgently needed for patients undergoing large hepatic resections because avoidance of I/R damage may have an important impact on postoperative morbidity and mortality by improving the function of the remaining small liver. The attractiveness of rCT-1 as a potential drug in liver surgery is enhanced by the striking increase in the number of hepatic surgical interventions during the last years owing to the frequent practice of major hepatic resections for primary or metastatic liver cancer and the increasing application of living donor liver transplantation.
MATERIAL AND METHODS
Animals.
We followed University of Navarra guidelines for the use of laboratory animals. Male Wistar rats (250-275 g) were from Harlan. C57/BL6 CT-1-null mice (CT-1 −/− ) (22) and WT mice were a gift from Dr. M. Selzner (Zurich University Hospital, Zurich, Switzerland). C57/BL6 IL-6-null mice (IL-6 −/− ) were from The Jackson Laboratory.
Surgical procedure. Rats anesthetized with isofl urane (Abbott) were subjected to segmental hepatic ischemia followed by reperfusion (23) . They were killed after 1 h of ischemia and 6 or 12 of reperfusion (I/R), and serum and liver biopsies were harvested. Sham animals were manipulated identically but without vascular clamping.
A similar I/R procedure was performed in CT-1 -/-and WT male mice 8-10 wk old (5) . The left and median lobes were occluded for 75 min, and after 3 h of reperfusion mice were killed for blood and tissue sampling. Where indicated IP consisting of 10 min of ischemia followed by 15 min of reperfusion was performed before I/R. Also where indicated, goat preimmune IgG (Sigma-Aldrich) or CT-1-neutralizing antibodies (R&D Systems) were administered i.v. to WT mice 15 min before IP+I/R. WT, CT-1 -/-, and IL-6 -/-mice were subjected to brief ischemia of 10 min and killed after 15 min of reperfusion.
Liver samples were snap frozen in liquid nitrogen or formalin fi xed and paraffi n embedded for histological studies. Serum was used for AST and ALT aminotransferases analysis.
Rats were given 400 μg/kg body weight of rCT-1 (8) i.v. 10 min before ischemia or 800 μg/kg body weight just after declamping. In mice 400 μg/kg body weight of rCT-1 was injected 10 min before ischemia. These doses were selected based on dose-response studies performed in mice and were extrapolated to rat experiments. In these experiments, a clear protective eff ect was already observed at 200 μg/kg body weight of rCT-1, and protection was maximal at 400 μg/kg body weight. The rCT-1 that was used for these studies contained 0.14 pg/μg protein of LPS (Limulus amoebocyte lysate assay; Cambrex).
Histological analysis. Hematoxylin and eosin (H&E) staining and TU-NEL assay (Roche Applied Science) were performed on paraffi n-embedded liver sections as described (8, 24) . Immunohistochemistry was performed on paraffi n-embedded liver sections using a polyclonal anti-P-STAT3 (tyr 705) antibody (Cell Signaling) (25) . The EnVision kit (Dako) was used for detection.
Western blot. Western blot was performed (24) using antibodies specifi c for caspase 3, P-STAT3 (tyr 705), STAT3, P-Akt, Akt (Cell Signaling), P-JNK, P-c-Jun (Santa Cruz Biotechnology, Inc), actin (Sigma-Aldrich), and CT-1 (R&D Systems).
In vitro studies. Mouse primary hepatocytes were isolated and cultured as described (25) . After adhesion, hepatocytes were treated for 30 or 60 min with 500 μM of tBuOOH (Sigma-Aldrich). Cells were lysed for Western blot analyses as previously described (24) . Conditioned medium was harvested and concentrated before Western blot analysis. Cell viability was not aff ected by tBuOOH treatment because no diff erences were observed in lactate dehydrogenase activity between the supernatant of control and treated hepatocytes, as assessed by the CytoTox-ONE assay from Promega.
Statistical analysis. Statistical methods used were as described previously (26) . Data are means ± SD; a p value of < 0.05 was considered signifi cant.
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